Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2005:3–20. doi: 10.1007/3-7643-7381-4_1

Economic aspects of vaccines and vaccination: a global perspective

Philippe PA Beutels 6,7
Editors: Stefan HE Kaufmann4, Paul-Henri Lambert5
PMCID: PMC7123384

The content is available as a PDF (169.5 KB).

References

  • 1.World Bank (2004) World Development Indicators, online publication available on CD ROM and at http://publications.worldbank.org/ecommerce/catalog/ product?item_id=631625
  • 2.WHO (2001) Commission on Macroeconomics and Health: investing in health for economic development. Available at http://www.cid.harvard.edu/cidcmh/ CMHReport.pdf
  • 3.Razzell P.E. The conquest of smallpox. Firle (UK): Caliban Books; 1977. [Google Scholar]
  • 4.McKeown T., Record R.G., Brown R.G. An interpretation of the modern rise of population in Europe. Population Studies. 1972;26:345–382. [PubMed] [Google Scholar]
  • 5.Beutels P. Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. Antwerp: University of Antwerp; 2002. [Google Scholar]
  • 6.Philipson T. Economic epidemiology and infectious disease. In: Newhouse J., Culyer T., editors. Handbook of health economics. New York: North-Holland; 2000. pp. 1761–1797. [Google Scholar]
  • 7.Anderson R.M., May R.M. Infectious diseases of humans — dynamics and control. Oxford: Oxford University Press; 1991. [Google Scholar]
  • 8.Panagiotopoulos T., Antoniadou I., Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. Brit Med J. 1999;319(7223):1462–1467. doi: 10.1136/bmj.319.7223.1462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Barrett S. Economics of eradication vs control of infectious diseases. Bull WHO. 2004;82(9):639–718. [PMC free article] [PubMed] [Google Scholar]
  • 10.Kaddar M. Lecture at the advanced course in vaccinology. Seoul: International Vaccine Institute; 2004. [Google Scholar]
  • 11.Smith RD, Sommers T (2003) Assessing the economic impact of communicable disease outbreaks: the case of SARS. Working paper WHO, July 2003
  • 12.Lee JW, McKibbin W (2004) Globalization and Disease: The Case of SARS. Asian Economic Papers 3(1); in press
  • 13.Drummond M., O’Brien B., Stoddart G., Torrance G. Methods for the economic evaluation of health care programmes. second ed. Oxford: Oxford University Press; 1997. [Google Scholar]
  • 14.Edmunds W.J., Dejene A., Mekonnen Y., Haile M., Alemnu W., Nokes D.J. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy and Planning. 2000;15(4):408–416. doi: 10.1093/heapol/15.4.408. [DOI] [PubMed] [Google Scholar]
  • 15.Hall A.J., Robertson R.L., Crivelli P.E., Lowe Y., Inskip H., Snow S.K., Whittle H. Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans Roy Soc Trop Med Hyg. 1993;87:333–336. doi: 10.1016/0035-9203(93)90154-i. [DOI] [PubMed] [Google Scholar]
  • 16.Drummond M. Output measurement for resource allocation decisions in health care. In: McGuire A., Fenn P., Mayhew K., editors. Providing health care. The economics of alternative systems of finance and delivery. Oxford: University Press; 1991. pp. 99–119. [Google Scholar]
  • 17.Beutels P., Van Doorslaer E., Van Damme P., Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Exp Rev Vacc. 2003;2(5):89–100. doi: 10.1586/14760584.2.5.649. [DOI] [PubMed] [Google Scholar]
  • 18.Mooney G. The economics of health and medicine. Brighton: Wheatsheaf; 1992. [Google Scholar]
  • 19.Luce B.R., Manning W.G., Siegel J.E., Lipscomb J. Estimating costs in costeffectiveness analysis. In: Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. pp. 176–213. [Google Scholar]
  • 20.Mishan E.J. Evaluation of life and limb: a theoretical approach. Journal of Political Economy. 1971;79:687–706. [Google Scholar]
  • 21.Olsen J.A., Smith R.D. Theory versus practice: a review of “willingness to pay” in health and health care. Health Econ. 2001;10:39–52. doi: 10.1002/1099-1050(200101)10:1<39::AID-HEC563>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  • 22.Keeler J., Cretin S. Discounting of life saving and other non-monetary effects. Management Science. 1983;29(3):300–306. doi: 10.1287/mnsc.29.3.300. [DOI] [Google Scholar]
  • 23.Weinstein M.C., Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716–721. doi: 10.1056/NEJM197703312961304. [DOI] [PubMed] [Google Scholar]
  • 24.van Hout B.A. Discounting costs and effects: a reconsideration. Health Econ. 1998;7(7):581–594. doi: 10.1002/(sici)1099-1050(1998110)7:7<581::aid-hec380>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 25.Gravelle H., Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ. 2001;10(7):587–599. doi: 10.1002/hec.618. [DOI] [PubMed] [Google Scholar]
  • 26.Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437–452. doi: 10.1002/hec.864. [DOI] [PubMed] [Google Scholar]
  • 27.George B., Harris A., Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996) Pharmacoeconomics. 2001;19(11):1103–1109. doi: 10.2165/00019053-200119110-00004. [DOI] [PubMed] [Google Scholar]
  • 28.Chapman R.H., Stone P.W., Sandberg E.A., Bell C., Neumann P.J. A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Med Decis Making. 2000;20(4):451–467. doi: 10.1177/0272989X0002000409. [DOI] [PubMed] [Google Scholar]
  • 29.Tengs T.O., Adams M.E., Pliskin J.S., Safran D.G., Siegel J.E., Weinstein M.C., Graham J.D. Fivehundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15(3):369–390. doi: 10.1111/j.1539-6924.1995.tb00330.x. [DOI] [PubMed] [Google Scholar]
  • 30.Shearley A.E. The societal value of vaccination in developing countries. Vaccine. 1999;17(Suppl 3):S109–S112. doi: 10.1016/s0264-410x(99)00303-5. [DOI] [PubMed] [Google Scholar]
  • 31.Bishai D., Koenig M., Ali Khan M. Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Econ. 2003;12(5):415–419. doi: 10.1002/hec.732. [DOI] [PubMed] [Google Scholar]
  • 32.UNICEF (2001) The State of the World’s Children. Early childhood. Available at www.unicef.org/SOWC01
  • 33.Global Forum for Health Research (2004) The 10/90 gap report 2004. Available at http://www.globalforumhealth.org/pages/index.asp?ThePage=page1_419.asp
  • 34.Kaddar M., Lydon P., Levine R. Financial challenges of immunization: a look at GAVI. Bull WHO. 2004;82(9):697–702. [PMC free article] [PubMed] [Google Scholar]

Articles from The Grand Challenge for the Future are provided here courtesy of Nature Publishing Group

RESOURCES